Kyowa Pharmaceutical Industry Co., Ltd. (Headquarters: Osaka Prefecture, President: Noriaki Tsunoda, hereinafter Kyowa Pharmaceutical Industry) and FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) are recognized. We have signed a basic agreement regarding the business alliance regarding the disease diagnosis support system.

　The dementia diagnosis support system uses FRONTEO's original natural language analysis AI "Concept Encoder" to determine the presence or severity of cognitive dysfunction from a conversation between a patient and a doctor for about 5 to 10 minutes. It is a revolutionary system that is expected.This system is the world's first system for diagnosing dementia using natural language, and we are aiming for early commercialization in the medical field.

　The number of dementia patients in Japan is estimated to reach 2020 million in 630 * 1, and about 7 in 1 elderly people is said to have cognitive impairment * 2.On the other hand, it is difficult to diagnose dementia based on the test results alone, and specialized knowledge and experience are required for diagnosis. In Japan, which is facing a super-aging society, measures against dementia, which are increasing year by year, should be resolved immediately. It has become a national issue.

　Diagnosis of dementia requires specialized knowledge and experience from the diagnosing doctor, as well as the psychological burden on the patient being diagnosed, and the patient's repeated questions. However, there are many issues such as the learning effect of memorizing the question itself.

　This FRONTEO system is an epoch-making system that can judge cognitive function from short daily conversation, reduces the burden on both the diagnostician side and the examinee side, early detection of dementia and evaluation in a short cycle. It is expected to realize.

　With this basic agreement with Kyowa Yakuhin, FRONTEO will strengthen the research, development and sales system of this system, aiming for the first domestic regulatory approval of a dementia diagnosis system using natural language analysis AI.

The impact of this matter on FRONTEO's business results from the current fiscal year onward will be minor.

* 1 From the Ministry of Health, Labor and Welfare "Future Estimates for People with Dementia"

https://www.mhlw.go.jp/content/000524702.pdf

* 2 From the Ministry of Health, Labor and Welfare "Dementia Policy Promotion Charter [text]"

https://www.mhlw.go.jp/content/000522832.pdf

About Concept Encoder　URL: https://lifescience.fronteo.com/
Concept Encoder is an artificial intelligence (AI) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing healthcare-related medical data, which contains a large amount of free-form text data, based on evidence.We have introduced and realized statistical methods such as the significance test, which is indispensable for "evidence-based medicine (EBM)", which is a common understanding among healthcare professionals, in natural language analysis. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with "numerical data" such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. XNUMX

About Kyowa Pharmaceutical Industry Co., Ltd.　URL: http://www.kyowayakuhin.co.jp/
Kyowa Pharmaceutical Industry Co., Ltd. (Kyowa Pharmaceutical Industry Co., Ltd.) was founded in 1954 and has expanded its business centered on generic drugs under the "Amel" brand, focusing on the CNS (central nervous system) area.In addition to generic drugs, long-listed products, which were transferred from Shionogi in 2016, will be sold as new drugs for the treatment of depressive symptoms of bipolar disorder, which was commissioned by Astellas Pharma in 2017. We are also promoting further development in the CNS area by comprehensively providing new drugs.
In September 2019, in order to concentrate management resources on Kyowa Pharmaceutical itself, the shares and management rights of Kyowa Criticare Co., Ltd., a wholly-owned subsidiary specializing in injections acquired in 9, were transferred, and in 2011. In December, Unison Capital Group, a private equity fund with strengths in the healthcare field, achieved independence from the Lupine Group by transferring shares from the global pharmaceutical company Lupin Group using the LBO (Leveraged Buyout) method. ..
Kyowa Yakuhin has a new management vision of "Aiming to be a CNS Total Solution Company," and through the provision of products and services that go beyond pharmaceuticals, mainly in the CNS domain, patients and their families, healthcare professionals, and society. We will take on various challenges with the aim of becoming a company that can contribute to.
Sales for the year ended March 2019, 3 were 282 billion yen.

About FRONTEO　URL: https://www.fronteo.com/
FRONTEO Inc. has developed its own artificial intelligence engine "KIBIT".^®(Kibit) ”and“ concept encoder^®(Concept encoder) ”is a data analysis company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves, investigates, and analyzes electronic data necessary for international litigation, and digital forensic investigations.In-house developed data analysis platform "Lit i View"^®(Lit Eye View) ”,“ Predictive Coding Predictive Coding^®(Predictive Coding) ”technology is used to provide legal proceedings support to companies.The unique artificial intelligence-related technology cultivated and developed in this legal business learns "tacit knowledge" such as expert experience and intuition, and realizes prediction of future behavior from analysis of human thoughts.We have expanded into areas such as life science and business intelligence, and have achieved results in "work style reform" in addition to FinTech and RegTech. Listed on TSE Mothers on June 2007, 6.The capital is 26 thousand yen (as of March 2,559,206, 2019).